A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization
David I. Bernstein(Cincinnati Children's Hospital Medical Center), A. Louis Bourgeois(Program for Appropriate Technology in Health), Jill El-Khorazaty(Emmes (United States)), Amanda D. Buskirk(University of Maryland, Baltimore), Rebecca C. Brady(Cincinnati Children's Hospital Medical Center), Nicole Maier(Program for Appropriate Technology in Health), Rezwanul Wahid(University of Maryland, Baltimore), Holly Baughman(Emmes (United States)), Mitchell B. Cohen(Centre Hospitalier Universitaire Sainte-Justine), Marcela F. Pasetti(University of Maryland Global Campus), Marcelo B. Sztein(University of Maryland, Baltimore), Shahida Baqar(Naval Medical Research Command), Michelle Dickey(Cincinnati Children's Hospital Medical Center)
Cited by 36
Related Papers
The Underrecognized Burden of Influenza in Young Children
|New England Journal of Medicine|2006|879
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
Anaphylaxis—a practice parameter update 2015
|Annals of Allergy Asthma & Immunology|2015|473
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Atopic dermatitis: A practice parameter update 2012
|Journal of Allergy and Clinical Immunology|2013|416